Perrotti M, Rabbani F, Russo P, Solomon M C, Fair W R
Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Urology. 1998 Jul;52(1):106-10. doi: 10.1016/s0090-4295(98)00154-x.
Long-term cure after radical prostatectomy has been reported for men with organ-confined poorly differentiated prostate cancer. However, organ-confined rates have been disappointingly low, ranging from 8% to 18% in earlier series, which have consisted primarily of patients not screened for prostate-specific antigen (PSA). Recently, it has been our impression that a greater number of patients with poorly differentiated tumors have had organ-confined disease than earlier reports would have led us to predict.
To test this hypothesis, we reviewed the results of surgical staging in men with poorly differentiated tumors (Gleason score 8 to 10) entered into our prospective data base between August 1992 and June 1996.
Of 109 men undergoing operation during the study period, 64 underwent exploration for planned radical prostatectomy with no previous therapy and comprise the study cohort. In 92%, the initial presentation was an elevated PSA level (median 10.8 ng/mL). We observed an organ-confined rate of 30% and found preoperative PSA levels of 10 ng/mL or less to be a significant predictor of organ-confined disease (45% versus 17%, P = 0.016, chi-square test). On preliminary follow-up (median 31 months), 84% of men with organ-confined tumors are free of PSA relapse, similar to that seen in 233 men with organ-confined moderately differentiated tumors undergoing operation during the study period (P = 0.12, log-rank test).
Early prostate cancer detection, as reflected by PSA levels of 10 ng/mL or less, is associated with a higher organ-confined rate in men with poorly differentiated tumors. On preliminary follow-up, PSA relapse rates were lower in men with pathologically confirmed, organ-confined, poorly differentiated disease.
据报道,器官局限性低分化前列腺癌患者行根治性前列腺切除术后可实现长期治愈。然而,器官局限性发生率一直低得令人失望,在早期系列研究中为8%至18%,这些研究主要纳入的是未进行前列腺特异性抗原(PSA)筛查的患者。最近,我们感觉与早期报告的预测相比,更多低分化肿瘤患者患有器官局限性疾病。
为验证这一假设,我们回顾了1992年8月至1996年6月间纳入我们前瞻性数据库的低分化肿瘤(Gleason评分8至10)男性患者的手术分期结果。
在研究期间接受手术的109名男性中,64名接受了计划性根治性前列腺切除术探查且此前未接受过治疗,构成了研究队列。92%的患者最初表现为PSA水平升高(中位数为10.8 ng/mL)。我们观察到器官局限性发生率为30%,并发现术前PSA水平在10 ng/mL或更低是器官局限性疾病的显著预测因素(45%对17%,P = 0.016,卡方检验)。在初步随访(中位数31个月)中,84%的器官局限性肿瘤男性患者无PSA复发,这与研究期间接受手术的233名器官局限性中分化肿瘤男性患者的情况相似(P = 0.12,对数秩检验)。
PSA水平在10 ng/mL或更低所反映的早期前列腺癌检测与低分化肿瘤男性患者较高的器官局限性发生率相关。在初步随访中,病理证实为器官局限性低分化疾病的男性患者PSA复发率较低。